Vaccine Contract Manufacturing Market Report 2026

Vaccine Contract Manufacturing Market Overview

• Vaccine Contract Manufacturing market size has reached to $3.88 billion in 2025 • Expected to grow to $6.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Elevated Infectious Disease Cases Propel Expansion In The Vaccine Contract Manufacturing Market • Market Trend: Strategic Expansion With The Standalone Vaccine Contract Manufacturing Site • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vaccine Contract Manufacturing Market?

Vaccine contract manufacturing refers to an arrangement for creating vaccines with outside producers, who oversee producing, packing, and labeling vaccines according to the specifications and demands of the contracting business or organization. The primary benefit of vaccine contract manufacturing is that it simplifies production, resulting in cost savings and fewer difficulties. The main types of services involved in vaccine contract manufacturing are fill-finish and bulk products. Fill-finish refers to the filling and finishing of the manufacturing process of vaccines. In the pharmaceutical industry, finishing refers to the sterilization and standardization of vaccine components into the containers, while filling means simply adding them to containers and sealing them properly. The vaccines produced are inactivated vaccines, live-attenuated vaccines, RNA (ribonucleic acid) vaccines, subunit vaccines, and toxoid-based vaccines. These are prepared by downstream and upstream processes on preclinical, clinical, and commercial scales of operations for human use and veterinary end-users.

What Is The Vaccine Contract Manufacturing Market Growth Forecast?

The vaccine contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $6.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising demand for rapid vaccine scale-up capabilities, increasing investments in mRNA and next-generation vaccines, expansion of commercial-scale manufacturing, growing focus on regional vaccine self-sufficiency, adoption of advanced bioprocess technologies. Major trends in the forecast period include increasing outsourcing of vaccine production, rising demand for flexible manufacturing capacity, expansion of fill-finish service capabilities, growing focus on regulatory-compliant manufacturing, increasing adoption of single-use bioprocessing systems.

Global Vaccine Contract Manufacturing Market Segmentation

1) By Service Type: Fill-Finish, Bulk Product 2) By Vaccine Type: Inactivated Vaccines, Live-Attenuated Vaccines, RNA (Ribonucleic Acid) Vaccines, Subunit Vaccines, Toxoid-Based Vaccines 3) By Process: Downstream, Upstream 4) By Scale Of Operation: Preclinical, Clinical, Commercial 5) By End-Use: Human Use, Veterinary Subsegments: 1) By Fill-Finish: Aseptic Fill-Finish, Lyophilization, Vial Filling, Syringe Filling 2) By Bulk Product: Cell Culture, Microbial Fermentation, Antigen Production, Buffer Preparation

What Is The Driver Of The Vaccine Contract Manufacturing Market?

The rising infectious diseases worldwide are expected to boost the growth of the vaccine contract manufacturing market. Infectious diseases refer to disorders caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. When there is an outbreak of infectious diseases, such as influenza, measles, or emerging viruses, there is an urgent need for vaccines to prevent further spread. Contract manufacturers can quickly scale up production to respond to these outbreaks. For instance, in October 2024, according to the World Health Organization, a Switzerland-based international public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, placing tuberculosis as the leading infectious disease killer. Therefore, the rising infectious diseases worldwide are driving the growth of the vaccine contract manufacturing industry.

Key Players In The Global Vaccine Contract Manufacturing Market

Major companies operating in the vaccine contract manufacturing market are Pfizer Inc, Johnson & Johnson, AbbVie Inc., Sanofi, GlaxoSmithKline, Merck KGaA, Moderna, BioNTech, GSK Vaccines, AstraZeneca PLC, Ajinomoto Co. Inc., Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Serum Institute of India Pvt. Ltd, Samsung Biologics, WuXi Biologics, Novavax, Sinovac Biotech, Emergent BioSolutions Inc., Bio Farma, Hualan Biological Engineering, BioMARC, Bavarian Nordic A/S, AGC Biologics, IDT Biologika GmbH, Bharat Biotech, Goodwin Biotechnology Inc., Biofabri S.L

Global Vaccine Contract Manufacturing Market Trends and Insights

Major companies operating in the vaccine contract manufacturing market are focusing on the production site opening of vaccine contract manufacturing to sustain their position in the market. Production site opening of vaccine contract manufacturing refers to the establishment of a facility dedicated to the manufacturing and production of vaccines on a contractual basis. For instance, in September 2023, WuXi Vaccines, a China-based contract development and manufacturing organization (CDMO) specializing in vaccine discovery and production, launched its first standalone vaccine CDMO site in Suzhou, China. This expansion marks a milestone for the company, introducing increased capabilities for both drug substance and drug product manufacturing. WuXi Vaccines now offers a comprehensive range of services covering diverse vaccines, including process development, drug product development, and the production of clinical-scale drug substances (DS) and small-to-medium sterile drug products (DP). The new standalone site enhances WuXi Vaccines' capacity to contribute to the development and manufacturing of vaccines, playing a pivotal role in advancing global healthcare solutions.

What Are Latest Mergers And Acquisitions In The Vaccine Contract Manufacturing Market?

In October 2024, SK bioscience, a South Korea-based vaccine and biotech company, acquired controlling stakes of IDT Biologika for approximately $244 million. This acquisition aligns with SK bioscience's strategy to accelerate growth and aims to drive consolidated sales to KRW 1 trillion (approximately USD 757.6 million) within the next five years. The company also plans to expand further with the launch of next-generation pneumococcal vaccines, positioning itself for continued financial improvement beyond 2028. IDT Biologika, a German-based company vaccine contract development and manufacturing organizations (CDMO).

Regional Outlook

North America was the largest region in the vaccine contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the vaccine contract manufacturing market report forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vaccine Contract Manufacturing Market?

The vaccine contract manufacturing market consists of revenues earned by entities by providing services such as analytical, quality control studies, cell or virus banking, and cold chain services. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine contract manufacturing market also includes sales of synthetic vaccines and DNA (deoxyribonucleic acid) vaccines, which are used in providing vaccine contract manufacturing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vaccine Contract Manufacturing Market Report 2026?

The vaccine contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine contract manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.